Zambia Maintains Stable ARV Stock Levels at 82%, Says ZAMMSA 

The Zambia Medicines and Medical Supplies Agency (ZAMMSA) has reassured the nation that antiretroviral (ARV) stock levels remain stable and sufficient, currently standing at 82%. The announcement aims to allay concerns about potential shortages and underscores the country’s continued commitment to supporting people living with HIV.

According to Bradley Chingobe, Senior Manager for Corporate Communications at ZAMMSA, the current stock level reflects the strength and resilience of the agency’s supply chain systems.

“This level of stock availability reflects our robust logistics and procurement systems, which continue to enable uninterrupted delivery of life-saving ARV therapy across the country,” Chingobe said in a statement.

ZAMMSA reported that national reserves currently hold over three months’ worth of ARV stock, with ongoing systematic distribution to over 3,500 health facilities nationwide. The stock includes all ARV regimens, first-line, second-line, and third-line therapies, ensuring equitable access to treatment for all patients.

“Patients are strongly encouraged to collect their medications as prescribed from their respective health facilities without hesitation or delay,” Chingobe emphasized.

The agency reiterated its unwavering commitment to ensuring the timely availability of essential medicines, highlighting its collaboration with the Ministry of Health and cooperating partners to protect the integrity of the pharmaceutical supply chain.

ZAMMSA also encouraged the public to stay informed through official channels and consult healthcare providers for any concerns related to ARV availability.

“Together, we reaffirm our collective commitment to ensuring that no patient is left behind in Zambia’s HIV response,” Chingobe concluded.